Table 2.

Table summarizing the evidence about the therapeutic potential of the GPCRs examined in this article for ALS treatment.

Receptor/Receptor Family	Cellular Expression	Potential for ALS Treatment	References
Adenosine receptors	Circulatory, immune, respiratory, and nervous systems	Ambiguous	[30,31,32,33,34,35,36,37]
Purinergic receptors P2Y	Almost all human tissues	Antagonism	[38,39,40,41,42,43]
Chemokine receptors	Predominantly on leukocytes surface	CXCR3, CXCR4, and CCR2 Antagonism	[44,45,46,47]
Angiotensin II receptors	Adrenal cortex, kidneys, vascular and cardiac muscles, nervous system	AT1 Antagonism	[48,49,50]
Dopamine receptors	Arteries, heart, kidneys, CNS	D2R Agonism	[51,52,53,54,55,56,57,58]
Serotonin receptors	Almost all human tissues	Ambiguous	[59,60,61,62,63]
GPR17 receptor	CNS, kidneys, heart	Antagonism	[64,65,66,67,68,69,70,71]
Adrenergic receptor β2	GI tract, respiratory system, blood vessels, pancreas, nervous system	Agonism	[72,73]
Histamine receptors	GI tract, circulatory, immune, and nervous systems.	Ambiguous	[74,75,76,77]
Cannabinoid receptors	CNS and immune system	CB2 agonism	[78,79,80,81]
Prostaglandin E2 receptor	GI tract, kidneys, reproductive, skeletal, immune, and nervous systems.	Ambiguous	[82,83,84]
Vasoactive intestinal peptide receptors	Almost all human tissues	Agonism	[85,86,87,88,89]
Metabotropic glutamate receptors	Nervous system	mGluR I antagonism/mGluR II and mGluR III agonism	[90,91,92,93,94]